Valneva suspended from marketing chikungunya shot in U.S. over safety concerns
Source: SeekingAlpha
2025-08-23 07:04:09 ET
More on Valneva
- Valneva SE 2025 Q2 - Results - Earnings Call Presentation
- Valneva SE (VALN) Q2 2025 Earnings Call Transcript
- Valneva reports 1H results; reaffirms FY outlook
- FDA lifts pause on Valneva's chikungunya vaccine in elderly
- Seeking Alpha’s Quant Rating on Valneva
Read the full article on Seeking Alpha
For further details see:
Valneva suspended from marketing chikungunya shot in U.S. over safety concerns
Valneva SE
NASDAQ: VALN
VALN Trading
-0.1% G/L:
$10.47 Last:
8,966 Volume:
$10.50 Open:
VALN Latest News
October 01, 2025 04:20:00 pm
Ongoing Valneva SE (VALN) Investigation: Protect Your Rights - Contact Levi & Korsinsky
VALN Stock Data
$798,793,290
73,508,485
N/A
10
N/A
Biotechnology & Life Sciences
Healthcare
FR
Lyon
